What is it used for?
LUNSUMIO is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).LUNSUMIO is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Read the primary sourceThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Product details
- Active ingredient
- mosunetuzumabmosunetuzumab
- Form and strength
- CONCENTRATE · 30 mg / 30 mL; CONCENTRATE · 1 mg / 1 mLCONCENTRATE · 30 mg / 30 mL; CONCENTRATE · 1 mg / 1 mL
- Manufacturer / applicant
- GENENTECH, INC.GENENTECH, INC.
LUNSUMIO is a sterile, colorless solution for intravenous infusion available as: Injection: 1 mg/mL in a single-dose vial Injection: 30 mg/30 mL (1 mg/mL) in a single-dose vialLUNSUMIO is a sterile, colorless solution for intravenous infusion available as: Injection: 1 mg/mL in a single-dose vial Injection: 30 mg/30 mL (1 mg/mL) in a single-dose vial
Safety and clinical review
Cytokine release syndrome (CRS), including serious or life-threatening reactions, can occur in patients receiving LUNSUMIO. Initiate treatment with the LUNSUMIO step-up dosing schedule to reduce the risk of CRS. Withhold LUNSUMIO until CRS resolves or permanently discontinue based on severity .Cytokine release syndrome (CRS), including serious or life-threatening reactions, can occur in patients receiving LUNSUMIO. Initiate treatment with the LUNSUMIO step-up dosing schedule to reduce the risk of CRS. Withhold LUNSUMIO until CRS resolves or permanently discontinue based on severity .
- Cytokine Release SyndromeCytokine Release Syndrome
- Neurologic Toxicity, including Immune Effector Cell-Associated Neurotoxicity SyndromeNeurologic Toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome
- InfectionsInfections
- Hemophagocytic LymphohistiocytosisHemophagocytic Lymphohistiocytosis
- CytopeniasCytopenias
- Tumor FlareTumor Flare
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Read the primary sourcePrepare your enquiry
Include the brand or generic name, strength, dosage form, requested quantity and country where care is needed. You can attach a prescription when you continue.
Questions patients ask
What is Lunsumio used for?
LUNSUMIO is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).LUNSUMIO is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Which formulation of Lunsumio should I ask about?
CONCENTRATE · 30 mg / 30 mL; CONCENTRATE · 1 mg / 1 mLCONCENTRATE · 30 mg / 30 mL; CONCENTRATE · 1 mg / 1 mL
Read the primary sourceWhat determines the price of Lunsumio?
A current quote depends on the exact presentation, quantity, provider and access arrangements. A catalogue entry is not a stock or delivery promise. Medical charges are paid to the provider, separately from coordination fees.
What should I check before using Lunsumio?
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Sources and review scope
FDA prescribing informationThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.